Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GMAB 
Genmab AS (GMAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: GMAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.24
1 Year Target Price $37.24
| 4 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.49% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.66B USD | Price to earnings Ratio 13.85 | 1Y Target Price 37.24 |
Price to earnings Ratio 13.85 | 1Y Target Price 37.24 | ||
Volume (30-day avg) 9 | Beta 0.79 | 52 Weeks Range 17.23 - 33.65 | Updated Date 12/2/2025 |
52 Weeks Range 17.23 - 33.65 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.29 |
Earnings Date
Report Date 2025-11-06 | When After Market | Estimate 0.45 | Actual 0.65 |
Profitability
Profit Margin 41.17% | Operating Margin (TTM) 44.91% |
Management Effectiveness
Return on Assets (TTM) 13.38% | Return on Equity (TTM) 29.41% |
Valuation
Trailing PE 13.85 | Forward PE 11.55 | Enterprise Value 16239472213 | Price to Sales(TTM) 5.11 |
Enterprise Value 16239472213 | Price to Sales(TTM) 5.11 | ||
Enterprise Value to Revenue 4.68 | Enterprise Value to EBITDA 9.51 | Shares Outstanding 615993070 | Shares Floating 60850605 |
Shares Outstanding 615993070 | Shares Floating 60850605 | ||
Percent Insiders - | Percent Institutions 10.27 |
Upturn AI SWOT
Genmab AS
Company Overview
History and Background
Genmab AS is a biotechnology company founded in 1999 in Copenhagen, Denmark. It specializes in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other diseases. Genmab has achieved significant milestones, including the development and commercialization of several approved antibody products and the establishment of partnerships with major pharmaceutical companies.
Core Business Areas
- Antibody Therapeutics Development: Focuses on researching, developing, and manufacturing antibody therapeutics for various disease areas, primarily cancer.
- Partnerships and Licensing: Collaborates with pharmaceutical and biotechnology companies to co-develop and commercialize its antibody products, generating revenue through licensing agreements and royalties.
- Research and Innovation: Invests in innovative antibody technologies and platforms to discover and develop novel therapeutics.
Leadership and Structure
Genmab AS is led by a management team with expertise in biotechnology, drug development, and commercialization. The organizational structure is designed to facilitate efficient research, development, and commercialization of antibody therapeutics.
Top Products and Market Share
Key Offerings
- Darzalex (daratumumab): A CD38-directed antibody approved for the treatment of multiple myeloma. Developed and commercialized in collaboration with Johnson & Johnson (JNJ). In 2023, Darzalex generated $9.1 billion USD in revenue. Competitors include other multiple myeloma treatments like Revlimid (acquired by Bristol Myers Squibb), Pomalyst (Celgene/Bristol Myers Squibb), and Velcade (Takeda).
- Kesimpta (ofatumumab): A CD20-directed antibody approved for the treatment of relapsing forms of multiple sclerosis (RMS). Developed in collaboration with Novartis (NVS). Market share for MS therapies is fragmented. Competitors include other MS drugs like Ocrevus (Roche), Tysabri (Biogen), and Gilenya (Novartis).
- Tivdak (tisotumab vedotin-tftv): A tissue factor (TF)-directed antibody drug conjugate (ADC) approved for treatment of recurrent or metastatic cervical cancer. Developed in collaboration with Seagen (now part of Pfizer). Competitors include chemotherapy regimens and other targeted therapies for cervical cancer.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, rapid technological advancements, and high regulatory scrutiny. There's increasing demand for novel therapeutics, especially in oncology and autoimmune diseases.
Positioning
Genmab AS is a leading biotechnology company specializing in antibody therapeutics. Its competitive advantage lies in its innovative antibody technologies, strong partnerships, and successful track record of developing and commercializing antibody products.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars globally. Genmab is well-positioned to capture a significant share of this market through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong antibody technology platforms
- Successful track record of drug development
- Established partnerships with major pharmaceutical companies
- Diversified product pipeline
- Experienced management team
Weaknesses
- Reliance on partnerships for commercialization
- High R&D expenses
- Competition from larger pharmaceutical companies
- Clinical trial risks
- Dependence on key products like Darzalex
Opportunities
- Expansion into new therapeutic areas
- Development of next-generation antibody therapeutics
- Strategic acquisitions and collaborations
- Growing demand for antibody-based therapies
- Geographic expansion
Threats
- Competition from biosimilars
- Regulatory hurdles and delays
- Patent expirations
- Economic downturns
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- NVS
- PFE
- BMY
- RHHBY
- BIIB
- TAK
Competitive Landscape
Genmab AS competes with larger pharmaceutical and biotechnology companies. Genmab has an advantage in the speed and success rates of discovering novel antibody therapeutics.
Major Acquisitions
ProBioGen AG
- Year: 2024
- Acquisition Price (USD millions): 140
- Strategic Rationale: Provides Genmab with proprietary cell line technology to enhance antibody drug development and manufacturing.
Growth Trajectory and Initiatives
Historical Growth: Genmab AS has experienced strong revenue and earnings growth over the past decade, driven by the commercial success of Darzalex and Kesimpta.
Future Projections: Analysts project continued revenue and earnings growth for Genmab AS, driven by the expansion of its existing products and the development of new antibody therapeutics. Revenue growth is expected to average around 15% annually over the next 3 years
Recent Initiatives: Genmab AS has recently invested in expanding its antibody technology platforms and pipeline, as well as forging new partnerships with pharmaceutical companies.
Summary
Genmab AS is a strong biotechnology company specializing in antibody therapeutics with successful products and partnerships. The company benefits from innovative technology and pipeline expansion. However, Genmab faces competition and relies on collaborations. Continued growth depends on navigating these challenges and capitalizing on market opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Genmab AS Annual Reports
- Company Filings
- Analyst Reports
- Press Releases
- Industry News Sources
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance can change over time, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genmab AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2009-06-01 | Co-Founder, President & CEO Dr. Jan G.J. van de Winkel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2681 | Website https://www.genmab.com |
Full time employees 2681 | Website https://www.genmab.com | ||
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.